Ergomed Plc (LON:ERGO), the pharma services and drug development firm, said finance chief Stephen Stamp has been appointed chief executive after Dr Dan Weng decided to step down with immediate effect.
Meanwhile, Dr Jan Petracek becomes chief operating officer and a board director. A search for a new chief financial officer will now take place.
WATCH: Ergomed Plc adds to co-development pipeline with Allergy Therapeutics deal
"Stephen has exceptionally wide business experience and has developed a deep understanding of Ergomed and its markets," said Peter George, the chairman of Ergomed.
"His move to CEO makes strong strategic sense as the company looks to continue to deliver on its strategy. I am also delighted to have Jan join the Board as COO.
"He has added significant value to the executive management team since joining Ergomed in 2016 and his vision and drive has contributed substantially to our pharmacovigilance business which continues to significantly outpace the growth of a fast growing market."
READ: Ergomed hopes to have PeproStat on the market by 2020 as it sails through Phase II trials
Stamp has held senior roles at a number of healthcare businesses in the UK and US and, as chief financial officer, led the IPO (initial public offering) of Shire on the London Stock Exchange and NASDAQ as well as a number of major acquisitions.
In late afternoon trading, Ergomed shares held steady at 187.5p.
-- Adds share price --